Improving Understanding and Acceptance of Biosimilars in the United States

Samsung Bioepis launches white paper highlighting barriers and opportunities to drive biosimilar adoption in the United States.

Samsung Bioepis launched a new white paper ‘Improving the Understanding and Acceptance of Biosimilars in the United States.’ The new white paper, developed based on research in 2021, highlights current perceptions, knowledge gaps, and barriers within the U.S. healthcare environment that are stymying adoption of biosimilars, and outlines potential strategies and incentives to help expand biosimilars’ use to help reduce healthcare costs while maintaining a high standard of patient care. The report is informed by the insights of key opinion leaders and subject matter experts, including doctors, pharmacists, nurses, patient advocates, and drug policy experts, who participated in three virtual expert panel sessions held in June-July 2021.

Link to Press Release on Samsung Bioepis website